Peripheral Vascular Effects of Insulin in Obesity

NCT07874945 | Not Yet Recruiting Early Phase 1 DMC FDA Drug

• 1 other identifier: 2136294
• Study Type: interventional
• Target: 64
• Locations: 0 countries
• Sites: N/A

Brief Summary

Successful completion of this project will advance our understanding of the role sympathetic nervous system overactivity plays in driving skeletal muscle malperfusion during hyperinsulinemia and consequently impaired glucose uptake in obesity.

Conditions

Obesity (BMI>30); Insulin Resistance

Outcome Measures

Primary Outcomes (1)

• Forearm blood flow

  5-minute resting average

Study Arms (2)

Healthy normal weight adults

EXPERIMENTAL

Healthy normal weight adults

Drug: human insulin

Individuals with obesity and comorbid IR

EXPERIMENTAL

Individuals with obesity and comorbid insulin resistance

Drug: human insulin

Interventions

human insulin DRUG

Participants will be administered intra-arterial insulin

Healthy normal weight adults; Individuals with obesity and comorbid IR

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \- 18 to 65 years of age
• Individuals with obesity and comorbid IR
• BMI 30-45 kg/m2
• Waist circumference ≥102 cm (men) or ≥88 cm (women)
• HOMA-IR ≥2.5
• Healthy normal weight adults
• BMI 18-25 kg/m2
• Waist circumference \<94 cm (men) and \<80 cm (women)
• HOMA-IR \<2

You may not qualify if:

• Pregnancy, breastfeeding
• Unable to provide consent
• Diabetes or polycystic ovarian syndrome
• Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease, stroke
• Nerve/neurologic disease
• Uncontrolled hypertension (systolic blood pressure \>180 mmHg and/or diastolic blood pressure \>100 mmHg)
• Active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin)
• Current smoking, tobacco, nicotine use
• Use of pharmacological therapy for weight loss
• Body weight change \>10% within the last 6 months
• Sensitivity to lidocaine
• Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy
• History of hypersensitivity to nitrates

Sponsors & Collaborators

• University of Missouri-Columbia: lead

MeSH Terms

Conditions

Obesity; Insulin Resistance

Interventions

Insulin

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases

Intervention Hierarchy (Ancestors)

Proinsulin; Insulins; Pancreatic Hormones; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Peptides; Amino Acids, Peptides, and Proteins

Central Study Contacts

Jacqueline Limberg

CONTACT

573-882-2544; limberglab@missouri.edu

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: October 4, 2026
• First Posted: October 15, 2026
• Study Start (Estimated): December 1, 2026
• Primary Completion (Estimated): June 1, 2031
• Study Completion (Estimated): June 1, 2032
• Last Updated: October 15, 2026

Record last verified: 2026-10